Literature DB >> 29268332

Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505).

Shinkyo Yoon1, Dae Ho Lee1, Sang-We Kim1.   

Abstract

Entities:  

Year:  2017        PMID： 29268332      PMCID： PMC5723812          DOI： 10.21037/jtd.2017.09.12

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  23 in total

Review 1.  The PD-1-PD-L pathway in immunological tolerance.

Authors:  Taku Okazaki; Tasuku Honjo
Journal:  Trends Immunol       Date:  2006-02-24       Impact factor: 16.687

2.  Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).

Authors:  David E Gerber; James J Urbanic; Corey Langer; Chen Hu; I-Fen Chang; Bo Lu; Benjamin Movsas; Robert Jeraj; Walter J Curran; Jeffrey D Bradley
Journal:  Clin Lung Cancer       Date:  2016-10-26       Impact factor: 4.785

3.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

4.  Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Authors:  Jarushka Naidoo; Xuan Wang; Kaitlin M Woo; Tunc Iyriboz; Darragh Halpenny; Jane Cunningham; Jamie E Chaft; Neil H Segal; Margaret K Callahan; Alexander M Lesokhin; Jonathan Rosenberg; Martin H Voss; Charles M Rudin; Hira Rizvi; Xue Hou; Katherine Rodriguez; Melanie Albano; Ruth-Ann Gordon; Charles Leduc; Natasha Rekhtman; Bianca Harris; Alexander M Menzies; Alexander D Guminski; Matteo S Carlino; Benjamin Y Kong; Jedd D Wolchok; Michael A Postow; Georgina V Long; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

5.  Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.

Authors:  Katsuyuki Hotta; Jiichiro Sasaki; Sho Saeki; Nagio Takigawa; Kuniaki Katsui; Koichi Takayama; Naoyuki Nogami; Yoshiyuki Shioyama; Akihiro Bessho; Junji Kishimoto; Mitsune Tanimoto; Katsuyuki Kiura; Yukito Ichinose
Journal:  Clin Lung Cancer       Date:  2015-08-18       Impact factor: 4.785

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports.

Authors:  Chieh-Sheng Lu; Jin-Hwang Liu
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

8.  Radiation as an immunological adjuvant: current evidence on dose and fractionation.

Authors:  Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-10-26       Impact factor: 6.244

Review 9.  Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.

Authors:  Emily Feld; Leora Horn
Journal:  Onco Targets Ther       Date:  2017-07-24       Impact factor: 4.147

Review 10.  The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis.

Authors:  Hui Luo; Xinshuang Yu; Ning Liang; Jian Xie; Guodong Deng; Qiqi Liu; Jingxin Zhang; Jiandong Zhang; Hong Ge
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.